$144 Million

Krystal Biotech

Follow-on Offering

Bookrunner, February 2021

Krystal Biotech

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. Krystal’s proprietary Skin TARgeted Delivery (STAR-D) platform consists of a patented engineered viral vector based on herpes simplex virus 1 (HSV-1) and its skin-optimized gene transfer technology. Krystal currently has three clinical stage programs: KB105 for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), KB301 for wrinkles and acne scars, and B-VEC for dystrophic epidermolysis bullosa (DEB).